TELO Overview

Market Performance: Oil and gas exploration and production shares are down approximately 1.6%, with Venture Global experiencing a significant drop of about 19.6% and Amplify Energy down by about 5.5%.

Sector Laggards: The decline in oil and gas stocks is highlighted as part of the broader market trends, alongside other sectors such as pharmaceuticals.

U.S. Stock Market Update: U.S. stock futures declined following a mixed performance on Monday, with major indices showing slight decreases. The market is influenced by a deal between Advanced Micro Devices and OpenAI, which boosted AI-related stocks.

Government Shutdown Impact: The ongoing government shutdown has delayed the release of U.S. trade deficit data, with President Trump indicating a willingness to collaborate with Democrats on healthcare only after the government reopens.

Key Stock Movements: Trilogy Metals surged 180.38% after a White House investment announcement, while Applovin fell 2.56% amid an SEC investigation. Advanced Micro Devices rose 2.57% due to its deal with OpenAI, and Telomir Pharmaceuticals jumped 30.99% following positive study results.

Economic Outlook: Analysts predict a strong earnings season for Q3 2025, with expectations of low-teens earnings growth for the S&P 500, driven by AI investments and a resilient economy, despite potential tariff pressures.

Biotech Stock Gains: Small-cap biotech stocks TELO, PCSA, RVPH, NMTC, and BRTX experienced significant after-hours gains driven by speculative trading and company updates, despite the absence of new disclosures.

Telomir Pharmaceuticals (TELO): TELO shares surged 43% after-hours, attributed to renewed interest in its in vitro data showcasing Telomir-1's unique targeting capabilities in cancer therapies.

Processa Pharmaceuticals (PCSA): PCSA shares rose 32.6% in after-hours trading, continuing a rally from the regular session, with no recent official news or updates from the company.

NeuroOne Medical Technologies (NMTC): NMTC shares increased 9.5% after announcing a 163% rise in preliminary product revenue for fiscal year 2025, alongside an upcoming virtual webinar, which sparked investor interest.